Ask AI
Nursing Considerations for EGFRm NSCLC

CE

Plotting a Treatment Course for EGFR-Mutated NSCLC: Nursing Considerations and Skill-Based Training for Oncology Nurses and NPs

Nurse Practitioners/Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit 

Released: October 23, 2025

Expiration: April 22, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following most accurately describes the mechanism of action of amivantamab?

2.

A patient with newly diagnosed metastatic NSCLC and which of the following EGFR mutations detected with broad tissue-based NGS testing would be a candidate for first-line amivantamab + carboplatin/pemetrexed?

3.

Which of the following adverse events associated with osimertinib can be significantly increased in severity in patients who received an immune checkpoint inhibitor shortly before the TKI?

4.

Case: Rash Prevention With Amivantamab + Lazertinib



  • A 46-yr-old male never smoker presented with SOB and cough not improving with antibiotics

  • A mass was found on CXR; CT chest showed large lung mass with pleural effusion; MRI confirmed brain metastases; biopsy confirmed adenocarcinoma 

    • NGS revealed an EGFR exon 19 deletion mutation



  • The patient wanted to be aggressive in treating his disease while preserving QoL and being able to work and be around his friends and family

  • The patient was treated with amivantamab + lazertinib 

Based on data from the COCOON study, which of the following could be included in an optimal approach for rash prevention with amivantamab + lazertinib?